Physicians and scientists from the University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center will discuss the latest research and clinical trial results on combination therapies for breast cancer, a potential new treatment for patients with recurrent glioma, and advances in PSMA PET guided radiotherapy for patients with prostate cancer, among other topics, at the American Society of Clinical Oncology’s annual meeting.
At this year’s scientific forum, Dennis Slamon, MD, PhD, chair of hematology-oncology and director of clinical and translational research at the UCLA Jonsson Comprehensive Cancer Center, will present findings from the NATALEE clinical trial (abstract LBA500), which looks at adding ribociclib, a targeted therapy drug, to standard hormone therapy as adjuvant treatment for patients with early hormone-receptor positive/HER2 negative breast cancer.
Timothy Cloughesy, MD, professor of neuro-oncology at the David Geffen School of Medicine at UCLA, is the senior author of abstract LBA1, which highlights INDIGO clinical trial results, a global, randomized double-blinded, phase 3 study of vorasidenib verse placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation. The findings will be presented during the plenary session on June 4.
“In this time of remarkable and rapid advancement in cancer medicine, the data and experiences presented during these sessions at ASCO offer important insights into emerging areas of study and allow a critical open forum for participation with a wide range of top experts,” says Michael Teitell, MD, PhD, director of the UCLA Jonsson Comprehensive Cancer Center.
